Human Immunodeficiency Virus Type 1-Neutralizing Antibodies Raised to a Glycoprotein 41 Peptide Expressed on the Surface of a Plant Virus

AIDS Research and Human Retroviruses

Volumn 11, Issue 3, 1995, Pages 327-334

  Mclain, Lesley ^a   Porta, Claudine ^b   Lomonossoff, George P ^c   Durrani, Zarmina ^a   Dimmock, Nigel J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b Axis Genetics plc   (United Kingdom)

^c JOHN INNES CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTISERUM; GLYCOPROTEIN GP 41; NEUTRALIZING ANTIBODY; RNA; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CHIMERA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE INSERTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOGENICITY; MOSAIC VIRUS; MOUSE; NONHUMAN; PEA; PLANT VIRUS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VIRION; VIRUS NEUTRALIZATION;

ANIMAL; ANTIBODY SPECIFICITY; CAPSID; CELL LINE; CLONING, MOLECULAR; COMOVIRUS; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMAN; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; RECOMBINATION, GENETIC; SUPPORT, NON-U.S. GOV'T; VIRION;

EID: 0028923242     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.1995.11.327     Document Type: Article

References (51)

1. Dimmock NJ: Neutralization of animal viruses. Curr Topics Microbiol Immunol 1993;183:1-149.
2. Emini E, Nara PL, and Schleif WA: Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J Virol 1990;64:3674-3678.
3. Emini EA, Scheif WA, Nunberg JH, et ai: Prevention of HIV infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody. Nature (London) 1992;355:728-730.
4. Girard M, Kaczorek M, Pinter A, et ai: Immune response of chimpanzees to active immunization against HIV-1. J Cell Biochem 1990;14(Suppl. D):150.
5. Hu S-L, Klaniecki J, Dykers T, Sridhar P, and Travis BM: Neutralizing antibodies against HIV-1, BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoprotein and boosted with homologous gpl60. AIDS Res Hum Retroviruses 1991;7:615-620.
6. Parry C, McLain L, and Dimmock NJ: Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gpl60. AIDS Res Hum Retroviruses 1994;10:205-212.
7. Earl PL, Robert-Guroff M, Matthews TJ, Krohn K, London WT, and Moss B: Isolate-and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques. AIDS Res Hum Retroviruses 1989;5:23-32.
8. Zagury D, Léonard R, Fouchard M, et al.: Immunization against AIDS in humans. Nature (London) 1987;326:249-250.
9. Zagury D, Bernard J, Cheynier R, et al.: A group-specific anamnestic reaction against HIV-1 induced by a candidate vaccine. Nature (London) 1988;332:728-731.
10. Cooney EL, Collier AC, Greenberg PD, et al.: Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope by glycoprotein. Lancet 1991;337:567-572.
11. Picard O, Achour A, Bernard J, et al.: A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gpl60-immunized healthy seronegative humans: Evidence for persistent cell-mediated immunity. J AIDS 1992;5:539-546.
12. Montefiori DC, Graham BS, Kliks S, and Wright PF: Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gpl60. J Clin Invest 1992;12:429-439.
13. Hu S-L, Fultz PN, McClure HM, et al.: Effect of inmiunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature (London) 1987;328:721-723.
14. Pyle SW, Morein B, Bess JW, et al.: Immune response to im-munostimulatory complexes (ISCOMs) prepared from immunode-ficiency virus type 1 (HIV-1) or the HIV-1 external envelope protein (gpl20). Vaccine 1989;7:465-473.
15. Girard M et al.: Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc Natl Acad Sei USA 1991;88:542-546.
16. Neurath AR, Jiang S, Strick N, et al.: Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope. AIDS Res Hum Retroviruses 1991;7:813-824.
17. van Regenmortel MHV: Structural and functional approaches to the study of protein antigenicity. Immunol Today 1989; 10:266-272.
18. Clarke BE, Newton SE, Carrol AR, et al.: Improved immuno-genicity of a peptide epitope after fusion to hepatitis B core preotein. Nature (London) 1987;330:381-384.
19. Stahl S and Murray K: Immunogenicity of peptide fusions to hepatitis B core antigen. Proc Natl Acad Sei USA 1989;86: 6283-6387.
20. Valenzuela P, Coit D, Medina-Selby A, et al.: Antigen engineering in yeast: Synthesis and assembly of hybrid hepatitis B surface antigen-herpes simplex gD particles. Biotechnology 1985;3: 323-326.
21. Delpeyroux F, Chenciner N, Lim A, et al.: A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science 1986;233:472-475.
22. Adams SE, Dawson KM, Gull K, Kingsman SM, and Kingsman AJ: The expression of hybrid HIV-Ty virus-like particles in yeast. Nature (London) 1987;329:68-70.
23. Burke K, Dunn G, Ferguson M, Minor PD, and Almond JF: Antigen chimeras of poliovirus as potential new vaccines. Nature (London) 1988;332:81-82.
24. Evans DJ, McKeating JA, Meredith JM, et al.: An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature (London) 1989;339:385-388.
25. Dedieu J-F, Ronco J, van der Werf S. Hogle JM, Henin Y, and Girard M: Poliovirus chimeras expressing sequences from the principal neutralization domain of human imunodeficiency virus type 1. J Virol 1992;66:3161-3167.
26. Smith GP: Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985;228: 1315-1317.
27. Greenwood J, Willis AE, and Perham RN: Multiple display of foreign peptides on a filamentous bacteriophage. Peptides from Plasmodium falciparum circumsporozoite protein as antigens. J Mol Biol 1991;220:821-827.
28. Mastico RA, Talbot SJ, and Stockley PG: Multiple presentation of foreign peptides on the surface of an RNA-free bacteriophage cap-sid. J Gen Virol 1993;74:541-548.
29. Li S, Schulman JL, Moran T, Bona C, and Palese P: Influenza A virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes. J Virol 1992;66:399-404.
30. Li S et al.: Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human inmiunodeficiency virus type 1. J Virol 1993;67:6659-6666.
31. Stauffacher CV, Usha R, Harrington M, Schmidt T, Hosur M, and Johnson JE: The structure of cowpea mosaic virus at 3.5 Å resolution. In: Crystallography in Molecular Biology (Moras D, Drenth J, Strandberg B, Suck D, and Wilson K, Eds.). Plenum Publishing, New York, 1987, pp. 293-308.
32. Chen Z, Stauffacher CV, and Johnson JE: Capsid structure and RNA packaging in comoviruses. Semin Virol 1990;1:453-466.
33. Lomonossoff GP and Shanks M: The nucleotide sequence of cowpea mosaic virus B RNA. EMBO J 1983;2:2253-2258.
34. van Wezenbeek P, Verver J, Harmsen J, Vos P, and van Kämmen A: Primary structure and gene organization of the middle component RNA of cowpea mosaic virus. EMBO J 1983;2:941-946.
35. Goldbach R and van Kämmen A: Structure, replication and expression of the bipartite genome of cowpea mosaic virus. In: Molecular Plant Virology, Vol. 2 (Davies JW, Ed.). CRC Press, Boca Raton, Florida 1985, pp. 83-120.
36. Vos P, Jaegle M, Wellink J, et al: Infectious RNA transcripts derived from full-length cDNA copies of the genomic RNAs of cowpea mosaic virus. Virology 1988;166:33-41.
37. Eggen R, Verver R, Wellink J, de Jong A, Golbach R, and van Kämmen A: Improvements of the infectivity of in vitro transcripts from cloned cowpea mosaic virus cDNA: Impact of terminal nucleotide sequences. Virology 1989; 173:447-455.
38. Holness CL, Lomonossoff GP, Evans D, and Maule AJ: Identification of the initiation codons for translation of cowpea mosaic virus middle component RNA using site-directed mutagenesis of an infectious cDNA clone. Virology 1989;172:311-320.
39. Dessens JT and Lomonossoff GP: Mutational analysis of the putative catalytic triad of the cowpea mosaic virus 24K protease. Virology 1991;184:738-746.
40. Rohll JB, Holness CL, Lomonossoff GP, and Maule AJ: 3'-Terminal nucleotide sequences important for the accumulation of cowpea mosaic virus M-RNA. Virology 1993;193:672-679.
41. Usha R, Rohll J, Spall VE, et al.: Expression of an animal virus antigenic site on the surface of a plant virus partile. Virology 1993;197:366-374.
42. Porta C, Spall VE, Loveland J, Johnson JE, Barker PJ, and Lomonossoff GP: Development of cowpea mosaic virus as a high yielding system for the presentation of foreign peptides. Virology 1994;202:949-955.
43. Kennedy RC, Henkel RD, Pauletti D, et al: Antiserum to a synthetic peptide recognizes the HTLV-in envelope glycoprotein. Science 1986;231:1556-1559.
44. Chanh TC, Dreesman G, Kanda P, et al.: Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J 1986;5:3065-3071.
45. Dalgleish AG, Chanh TC, Kennedy RC, Kanda P, Clapham PR, and Weiss RA: Neutralization of diverse strains of HIV-1 by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 1988;165:209-215.
46. van Kanmien A and de Jager CP: Cowpea mosaic virus. In: CMI/AAB Descriptions of Plant Viruses, p. 1978, 1997.
47. Laemmli UK: Cleavage of structural proteins during the assembly of the head of the bacteriophage T4. Nature (London) 1970;227:680-685.
48. McLain L and Dimmock NJ: Single-and multi-hit kinetics of IgG-neutralization of human inmiunodeficiency virus type 1 by monoclonal antibodies. J Gen Virol 1994;75:1457-1460.
49. Lomonossoff GP and Johnson JE: The synthesis and structure of comovirus capsids. Prog Biophys Mol Biol 1991;55:107-137.
50. Vella C, Ferguson M, Dunn G, et al: Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HTV-l chimera. J Gen Virol 1993;74:2603-2607.
51. Mason HS, Lam DM-K, and Amtsen CJ: Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sei USA 1992;89:11745-11749.